Featured Research

from universities, journals, and other organizations

Experimental Drug Shows Promise In Treating Certain Lymphomas

Date:
April 20, 2008
Source:
University of Alabama at Birmingham
Summary:
Data showed that AME-133v had a potent tumor-halting response in patients with follicular lymphoma, a portion of lymphoma cases. Results add to research showing a new class of monoclonal antibodies like AME-133v may lengthen survival times, according to researchers at the University of Alabama at Birmingham.

New clinical data showed some cancer patients with recurrent lymphoma benefited from an experimental drug called AME-133v, said a researcher at the University of Alabama at Birmingham (UAB).

Related Articles


The data was presented April 15th during the 2008 annual meeting of the American Association for Cancer Research in San Diego.

Phase 1 clinical trial data showed AME-133v had a potent tumor-halting response in patients with a particular kind of cancer called follicular lymphoma, said Andres Forero, M.D., associate scientist at the UAB Comprehensive Cancer Center and lead presenter on the results.

"These first results suggest that AME-133v provides a mechanism of action that may be more potent and ultimately more effective than the treatments we have on hand," Forero said.

The testing was done in 22 patients treated at UAB and at other locations around the nation. Follicular lymphoma patients are being enrolled in a Phase 2 study.

About 22 percent of the lymphomas in the United States are of the follicular type, according to the American Cancer Society. The malignant cells tend to grow slowly in a circular pattern in the lymph nodes. Follicular lymphoma can be treated with chemotherapy, but the disease often returns after therapy is complete.

Research has shown that a new class of anticancer agents like AME-133v, a group called monoclonal antibodies, can lengthen survival times, Forero said.

In the UAB study, AME-133v was administered in combination with a standard chemotherapy agent sometime after the initial treatments had been given, and after the re-emergence of cancer.

The experimental drug triggered signaling pathways within cells that slow or stop lymphoma cancer's growth, and the drug combo was well-tolerated by the body and caused minimal side effects, Forero said.

The Phase 1 study was a partnership between UAB, the University of California at Los Angeles, the Cleveland Clinic Taussig Cancer Institute, Stanford University Cancer Center in Palo Alto, Calif., the Nevada Cancer Institute in Las Vegas, Fox Chase Cancer Center in Philadelphia and the Holden Comprehensive Cancer Center at the University of Iowa in Iowa City. Study funding came from Eli Lilly & Co., which is currently investigating AME-133v.

Editor's note: Forero maintains a consulting relationship with Eli Lilly & Co.


Story Source:

The above story is based on materials provided by University of Alabama at Birmingham. Note: Materials may be edited for content and length.


Cite This Page:

University of Alabama at Birmingham. "Experimental Drug Shows Promise In Treating Certain Lymphomas." ScienceDaily. ScienceDaily, 20 April 2008. <www.sciencedaily.com/releases/2008/04/080416140930.htm>.
University of Alabama at Birmingham. (2008, April 20). Experimental Drug Shows Promise In Treating Certain Lymphomas. ScienceDaily. Retrieved October 26, 2014 from www.sciencedaily.com/releases/2008/04/080416140930.htm
University of Alabama at Birmingham. "Experimental Drug Shows Promise In Treating Certain Lymphomas." ScienceDaily. www.sciencedaily.com/releases/2008/04/080416140930.htm (accessed October 26, 2014).

Share This



More Health & Medicine News

Sunday, October 26, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Texas Nurse Nina Pham Cured of Ebola

Texas Nurse Nina Pham Cured of Ebola

AFP (Oct. 25, 2014) — An American nurse who contracted Ebola while caring for a Liberian patient in Texas has been declared free of the virus and will leave the hospital. Duration: 01:01 Video provided by AFP
Powered by NewsLook.com
Toxin-Packed Stem Cells Used To Kill Cancer

Toxin-Packed Stem Cells Used To Kill Cancer

Newsy (Oct. 25, 2014) — A Harvard University Research Team created genetically engineered stem cells that are able to kill cancer cells, while leaving other cells unharmed. Video provided by Newsy
Powered by NewsLook.com
IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) — IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) — A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins